Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Alrizomadlin · APG-115, AA-115

Small molecule · Inhibitor of MDM2 · developed by Ascentage Pharma Group

Phase 1/2 Most advanced trial
AAPG Developer
1 Registered trials

What is Alrizomadlin?

Alrizomadlin is an orally available MDM2 inhibitor that prevents MDM2 from binding p53, restoring p53 signaling and inducing tumor cell apoptosis. It is being studied in liposarcoma and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
APG-115, AA-115
Drug type
Small molecule
Targets
MDM2, p53 (TP53) (binding partner it blocks)
Mechanism
Inhibitor of MDM2
Pathways
p53 signaling, apoptosis
Therapy area
Oncology
Developer
Ascentage Pharma Group Inc. (AAPG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
15QAU0SI9J

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04785196 Phase 1/2 Liposarcoma Recruiting AAPG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorLiposarcoma

More from Ascentage Pharma Group

APG-2449 Phase 1 APG-3288 Phase 1 APG-5918 Phase 1 Dasminapant Phase 1/2 Lisaftoclax Phase 3 Olverembatinib Phase 3 Pelcitoclax Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.

Follow AAPG, the company behind Alrizomadlin

See AAPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AAPG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.